Clinical outcomes of hypertensive patients with COVID-19 receiving calcium channel blockers : a systematic review and meta-analysis
© 2021. The Author(s), under exclusive licence to The Japanese Society of Hypertension..
We aimed to perform a systematic review and meta-analysis to determine the overall effect of the preadmission/prediagnosis use of calcium channel blockers (CCBs) on the clinical outcomes in hypertensive patients with COVID-19. A systematic literature search with no language restriction was conducted in electronic databases in July 2021 to identify eligible studies. A random-effects model was used to estimate the pooled summary measure for outcomes of interest with the preadmission/prediagnosis use of CCBs relative to the nonuse of CCBs at 95% confidence intervals (CIs). The meta-analysis revealed a significant reduction in the odds of all-cause mortality with the preadmission/prediagnosis use of CCBs relative to the nonuse of CCBs (pooled OR = 0.65; 95% CI 0.49-0.86) and a significant reduction in the odds of severe illness with preadmission/prediagnosis use of CCBs relative to the nonuse of CCBs (pooled OR = 0.61; 95% CI 0.44-0.84), and is associated with adequate evidence to reject the model hypothesis of 'no significant difference' at the current sample size. The potential protective effects offered by CCBs in hypertensive patients with COVID-19 merit large-scale prospective investigations.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:45 |
|---|---|
| Enthalten in: |
Hypertension research : official journal of the Japanese Society of Hypertension - 45(2022), 2 vom: 09. Feb., Seite 360-363 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kow, Chia Siang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antihypertensive |
|---|
| Anmerkungen: |
Date Completed 21.01.2022 Date Revised 18.04.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41440-021-00786-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM332920666 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM332920666 | ||
| 003 | DE-627 | ||
| 005 | 20231225220553.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41440-021-00786-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1109.xml |
| 035 | |a (DE-627)NLM332920666 | ||
| 035 | |a (NLM)34754084 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kow, Chia Siang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical outcomes of hypertensive patients with COVID-19 receiving calcium channel blockers |b a systematic review and meta-analysis |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.01.2022 | ||
| 500 | |a Date Revised 18.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. The Author(s), under exclusive licence to The Japanese Society of Hypertension. | ||
| 520 | |a We aimed to perform a systematic review and meta-analysis to determine the overall effect of the preadmission/prediagnosis use of calcium channel blockers (CCBs) on the clinical outcomes in hypertensive patients with COVID-19. A systematic literature search with no language restriction was conducted in electronic databases in July 2021 to identify eligible studies. A random-effects model was used to estimate the pooled summary measure for outcomes of interest with the preadmission/prediagnosis use of CCBs relative to the nonuse of CCBs at 95% confidence intervals (CIs). The meta-analysis revealed a significant reduction in the odds of all-cause mortality with the preadmission/prediagnosis use of CCBs relative to the nonuse of CCBs (pooled OR = 0.65; 95% CI 0.49-0.86) and a significant reduction in the odds of severe illness with preadmission/prediagnosis use of CCBs relative to the nonuse of CCBs (pooled OR = 0.61; 95% CI 0.44-0.84), and is associated with adequate evidence to reject the model hypothesis of 'no significant difference' at the current sample size. The potential protective effects offered by CCBs in hypertensive patients with COVID-19 merit large-scale prospective investigations | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a CCB | |
| 650 | 4 | |a antihypertensive | |
| 650 | 4 | |a mortality | |
| 650 | 4 | |a severity | |
| 650 | 7 | |a Calcium Channel Blockers |2 NLM | |
| 700 | 1 | |a Ramachandram, Dinesh Sangarran |e verfasserin |4 aut | |
| 700 | 1 | |a Hasan, Syed Shahzad |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hypertension research : official journal of the Japanese Society of Hypertension |d 1996 |g 45(2022), 2 vom: 09. Feb., Seite 360-363 |w (DE-627)NLM075611406 |x 1348-4214 |7 nnns |
| 773 | 1 | 8 | |g volume:45 |g year:2022 |g number:2 |g day:09 |g month:02 |g pages:360-363 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41440-021-00786-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 45 |j 2022 |e 2 |b 09 |c 02 |h 360-363 | ||